Clinical Trial Update: Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intranasal scopolamine combined with sensory augmentation to mitigate motion sickness during spaceflight-related transitions a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Motion Sickness

Drugs mentioned

• Intranasal scopolamine (scopolamine)

Snippet

Sponsor: Repurposed Therapeutics, Inc. | Conditions: Motion Sickness, Space, Motion Simulation | Phase 2 | Status: RECRUITING